Notably, a 2018 study demonstrated the failure of a late-stage IDO inhibitor to treat patients with metastatic melanoma [102], suggesting the role of the kynurenine pathway in oncology may be more complex than currently understood. This evidence concerns the gene IDO1 and metastatic melanoma.